Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1 1Gilead Sciences gratefully acknowledges the patients, investigators, and study site personnel who participated in clinical trials GS-98-437 and GS-98-438
| Autor: | Huiling Yang, Shelly Xiong, Shan-Shan Chen, Craig S. Gibbs, Carol L. Brosgart, Stephanos J. Hadziyannis, William E. Delaney, Patrick Marcellin, Chris Westland, John Fry, Michael D. Miller, Robert G. Gish |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Hepatitis B virus
Hepatology biology business.industry Gastroenterology virus diseases biology.organism_classification medicine.disease_cause Virology digestive system diseases Orthohepadnavirus HBeAg Hepadnaviridae Immunology Genotype Adefovir medicine Viral disease Serostatus business medicine.drug |
| Zdroj: | Gastroenterology. 125:107-116 |
| ISSN: | 0016-5085 |
| Popis: | Background & aims: Hepatitis B virus (HBV) genotype may influence disease progression and antiviral response. We therefore analyzed the frequency and distribution of genotypes in patients from 2 multinational phase III studies of adefovir dipivoxil. Antiviral efficacy of adefovir dipivoxil 10-mg therapy was examined with respect to HBV genotype, hepatitis B e antigen (HBeAg) serostatus, and race. Methods: HBV genotypes were assigned by phylogenetic analyses of DNA sequences amplified from baseline serum samples (n = 694). Results: Patients from Asia/Oceania were infected predominantly with genotypes B and C, whereas patients from Western European countries were infected predominantly with genotypes A and D. In Mediterranean countries, genotype D was dominant. The most common genotype in North America was C, followed by A, B, and D. Regardless of location, Asian patients were infected predominantly with genotypes B or C, whereas Caucasian patients were infected predominantly with A or D. There were significant differences in the baseline serum HBV-DNA levels of patients infected with different HBV genotypes regardless of HBeAg serostatus. Forty-eight weeks of adefovir dipivoxil 10-mg therapy resulted in potent reductions in serum HBV DNA with no significant differences based on genotype, HBeAg status, or race; similarly, there was no statistical difference in HBeAg seroconversion rates between genotypes in these patients. Conclusions: HBV genotypes were distributed asymmetrically with respect to race, geography, and HBeAg status. Forty-eight weeks of adefovir dipivoxil therapy resulted in significant decreases in serum HBV-DNA levels in patients regardless of HBV genotype, HBeAg status, or race. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|